GH Research announces JAMA Psychiatry publication of Phase 2b GH001 results in treatment-resistant depression; reports efficacy independent of prior antidepressant failures

Reuters03-25
GH Research announces JAMA Psychiatry publication of Phase 2b GH001 results in treatment-resistant depression; reports efficacy independent of prior antidepressant failures
  • GH Research announced that Phase 2b results for mebufotenin (GH001) in treatment-resistant depression were published in the peer-reviewed journal JAMA Psychiatry under the title “GH001 vs Placebo in Patients with Treatment-Resistant Depression.”
  • The company said these findings had been previously presented in topline form, and the publication includes complete primary and secondary efficacy endpoints, safety and tolerability data, plus initial results from a 6-month open-label extension.
  • A separate peer-reviewed post hoc analysis titled “GH001 Efficacy is Independent of Prior Antidepressant Treatment Failures in Treatment-Resistant Depression: A Post Hoc Analysis of a Phase 2b Randomized Controlled Trial” is slated for a forthcoming issue of Psychopharmacology Bulletin.
  • GH Research reported the new analysis indicates GH001 efficacy is independent of the number of prior lifetime antidepressant treatment failures.
  • Chief Executive Officer Velichka Valcheva said the JAMA Psychiatry publication provides independent peer-reviewed validation supporting efforts to advance GH001 into global pivotal trials.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GH Research plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603251110PRIMZONEFULLFEED9678448) on March 25, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment